After calling Rockville, Maryland, home for more than eight years, GSK's vaccine and infectious disease R&D teams are ...

GSK delivered a mixed fourth-quarter report Wednesday, but GSK stock surged on its long-term outlook for more than $50 ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...

The report provides information and insights into GSK's tech activities, including: Insights of its digital transformation strategies and innovation programs. Overview of technology initiatives ...

GSK said it now e American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast.

UK's FTSE 100 firmed on Wednesday after two straight days of losses, buoyed by gains in shares of heavyweight GSK and gold ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks Consensus Estimate of 53 cents. Core earnings declined 20% year over ...

Clinical-stage biotechnology company Vaxxas has appointed three global vaccine experts as advisors as it progresses its ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...